Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
- PMID: 25877504
- DOI: 10.3899/jrheum.141261
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
Abstract
Objective: To seek insights into the heterogeneity of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA) through the analysis of a large patient sample collected in a multinational survey.
Methods: International pediatric rheumatologists and hemato-oncologists entered their patient data, collected retrospectively, in a Web-based database. The demographic, clinical, laboratory, histopathologic, therapeutic, and outcome data were analyzed in relation to (1) geographic location of caring hospital, (2) subspecialty of attending physician, (3) demonstration of hemophagocytosis, and (4) severity of clinical course.
Results: A total of 362 patients were included by 95 investigators from 33 countries. Demographic, clinical, laboratory, and histopathologic features were comparable among patients seen in diverse geographic areas or by different pediatric specialists. Patients seen in North America were given biologics more frequently. Patients entered by pediatric hemato-oncologists were treated more commonly with biologics and etoposide, whereas patients seen by pediatric rheumatologists more frequently received cyclosporine. Patients with demonstration of hemophagocytosis had shorter duration of sJIA at MAS onset, higher prevalence of hepatosplenomegaly, lower levels of platelets and fibrinogen, and were more frequently administered cyclosporine, intravenous immunoglobulin (IVIG), and etoposide. Patients with severe course were older, had longer duration of sJIA at MAS onset, had more full-blown clinical picture, and were more commonly given cyclosporine, IVIG, and etoposide.
Conclusion: The clinical spectrum of MAS is comparable across patients seen in different geographic settings or by diverse pediatric subspecialists. There was a disparity in the therapeutic choices among physicians that underscores the need to establish uniform therapeutic protocols.
Keywords: HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEMOPHAGOCYTIC SYNDROMES; MACROPHAGE ACTIVATION SYNDROME; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS.
Similar articles
-
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.Arthritis Rheumatol. 2014 Nov;66(11):3160-9. doi: 10.1002/art.38802. Arthritis Rheumatol. 2014. PMID: 25077692
-
Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.Rheumatol Int. 2016 Oct;36(10):1421-9. doi: 10.1007/s00296-016-3545-9. Epub 2016 Aug 10. Rheumatol Int. 2016. PMID: 27510530
-
Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis.Semin Arthritis Rheum. 2015 Feb;44(4):417-22. doi: 10.1016/j.semarthrit.2014.09.004. Epub 2014 Sep 11. Semin Arthritis Rheum. 2015. PMID: 25300700
-
Clinical features and correct diagnosis of macrophage activation syndrome.Expert Rev Clin Immunol. 2015;11(9):1043-53. doi: 10.1586/1744666X.2015.1058159. Epub 2015 Jun 16. Expert Rev Clin Immunol. 2015. PMID: 26082353 Review.
-
Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome.Pediatr Ann. 2015 Jun;44(6):e142-7. doi: 10.3928/00904481-20150611-09. Pediatr Ann. 2015. PMID: 26114369 Review.
Cited by
-
Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.Curr Treatm Opt Rheumatol. 2017 Mar;3(1):33-48. doi: 10.1007/s40674-017-0059-x. Epub 2017 Feb 7. Curr Treatm Opt Rheumatol. 2017. PMID: 28944163 Free PMC article.
-
Allogeneic Hematopoietic Cell Transplant for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.Case Rep Rheumatol. 2021 May 24;2021:9323141. doi: 10.1155/2021/9323141. eCollection 2021. Case Rep Rheumatol. 2021. PMID: 34123455 Free PMC article.
-
The Immunology of Macrophage Activation Syndrome.Front Immunol. 2019 Feb 1;10:119. doi: 10.3389/fimmu.2019.00119. eCollection 2019. Front Immunol. 2019. PMID: 30774631 Free PMC article. Review.
-
[Clinical and laboratory features of macrophage activation syndrome].Zhongguo Dang Dai Er Ke Za Zhi. 2017 Feb;19(2):188-192. doi: 10.7499/j.issn.1008-8830.2017.02.012. Zhongguo Dang Dai Er Ke Za Zhi. 2017. PMID: 28202118 Free PMC article. Chinese.
-
Macrophage activation syndrome in juvenile dermatomyositis: a systematic review.Rheumatol Int. 2020 May;40(5):695-702. doi: 10.1007/s00296-019-04442-1. Epub 2019 Sep 16. Rheumatol Int. 2020. PMID: 31529231
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical